The Atherothrombotic Diseases Market Will Increase from $36 Billion in 2012 to $47 Billion in 2022 Diagnosed Prevalent Cases of Atherothrombotic Disease Will Increase Steadily Through 2022, According to a New Report from Decision Resources
BURLINGTON, Mass., Dec. 19, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the launch of numerous add-on therapies in the atherothrombotic diseases market (incorporating pharmacotherapies for the treatment of coronary heart disease, peripheral arterial disease and ischemic stroke and transient ischemic attack) will drive the market to increase from $36 billion in 2012 to $47 billion in 2022. The launch of several premium-priced add-on therapies will offset the generic erosion of key brands and drive significant market growth during the second half of the study period (2017-2022).
The much-anticipated arrival of two antidyslipidemic drug classes, the cholesteryl ester transfer protein (CETP) inhibitors and the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, is expected to begin in 2017, with the launch of Eli Lilly's CETP inhibitor evacetrapib. With morbidity and mortality data available at launch, Decision Resources expects rapid uptake of these agents as add-on therapies, particularly in high-risk patients, significantly contributing to market growth from 2017 to 2022.
"Interviewed thought leaders are very excited about the potential of the emerging PCSK9 inhibitor drug class," said Decision Resources Senior Director Conor Walsh, Ph.D. "The clinical profile from Phase II data has been promising, combining strong reductions in LDL-C on top of statin therapy with an apparently good safety and tolerability profile. Although their injectable nature and anticipated high price will limit widespread use, we believe blockbuster status is achievable."
The Pharmacor advisory service report entitled Atherothrombotic Diseases, which will be published in the days ahead, finds that despite reductions in risk due to improved public health measures and primary prophylaxis, the number of diagnosed prevalent cases of atherothrombotic disease will rise steadily during the forecast period, driven by improvements in post-acute coronary syndrome and post-stroke survival, a greater proportion of cases being diagnosed and aging populations. This rise, along with the launch of high-priced add-on therapies, will boost the value of the atherothrombotic diseases market.
The report also finds that the overall value of the antithrombotic agent market will benefit from the expansion of current, premium-priced, oral antithrombotic agents, such as AstraZeneca's Brilinta/Brilique and Bayer/Janssen's Xarelto, into new indications, further eroding the dominance of clopidogrel (Bristol-Myers Squibb/Sanofi's Plavix/Iscover, generics). Further support will come from the launch of Merck's vorapaxar for the treatment of post-myocardial infarction patients.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
SOURCE Decision Resources